Scientists can now block heroin, morphine addiction
- Details
- Category: Research
In a major breakthrough, an international team of scientists has proven that addiction to morphine and heroin can be blocked, while at the same time increasing pain relief. The team from the University of Adelaide and University of Colorado has discovered the key mechanism in the body's immune system that amplifies addiction to opioid drugs.
Diabetes drugs raises risk of bladder cancer
- Details
- Category: Research
Researchers from the Perelman School of Medicine at the University of Pennsylvania found that patients taking thiazolidinedione (TZDs) drugs - which account for up to 20 percent of the drugs prescribed to diabetics in the United States - are two to three times more likely to develop bladder cancer than those who took a sulfonylurea drug, another common class of medications for diabetes.
Study adds to evidence daily aspirin linked to lower cancer mortality
- Details
- Category: Research
A large new observational study finds more evidence of an association between daily aspirin use and modestly lower cancer mortality, but suggests any reduction may be smaller than that observed in a recent analysis. The study, appearing early online in the Journal of the National Cancer Institute (JNCI), provides additional support for a potential benefit of daily aspirin use for cancer mortality, but the authors say important questions remain about the size of the potential benefit.
Scientists describe antibodies that protect against large variety of flu viruses
- Details
- Category: Research
A team led by scientists at The Scripps Research Institute and Crucell Vaccine Institute in the Netherlands describes three human antibodies that provide broad protection against Influenza B virus strains. The same team had previously reported finding broadly neutralizing antibodies against Influenza A strains.
Grapefruit juice lets patients take lower dose of cancer drug
- Details
- Category: Research
A glass a day of grapefruit juice lets patients derive the same benefits from an anti-cancer drug as they would get from more than three times as much of the drug by itself, according to a new clinical trial. The combination could help patients avoid side effects associated with high doses of the drug and reduce the cost of the medication.
Lower risk of serious side-effects in trials of new targeted drugs
- Details
- Category: Research
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis. Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust analysed data from 36 Phase I trials run by the organisations' joint Drug Development Unit.
Rejected Alzheimer's drug shows new potential
- Details
- Category: Research
An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.
More Pharma News ...
- Trial signals major milestone in hunt for new TB drugs
- Bloodstream scavenger inhibits clotting without increased bleeding
- Physicians don't adequately monitor patients' medication adherence
- Drug fails to curb heart bypass complications, but surgery gets safer
- Study finds drug warning labels need overhaul
- Patient-derived stem cells could improve drug research for Parkinson's
- A better way to test new treatments?